Day 1

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

solaci
solaci
418
0

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks follow-up LDL cholesterol reduction with alirocumab was 61% versus 0.8% placebo (p <0.0001). This reduction was maintained at 52 weeks. 

 

12_jennifer_robinson
Jennifer Robinson
2014-08-31

Original title: Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients.

 

Previous article
LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients
Next article
BIOSCIENCE study: Absorbable polymer versus permanent in sirolimus-eluting stents
solaci
solaci

More articles by this author

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

solaci - 0
The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

solaci - 0
180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

solaci - 0
The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

solaci - 0
The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic...
solaci -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

Dr. Omar Tupayachi - 0
The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

Dr. Omar Tupayachi - 0
As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...